1987
DOI: 10.1016/s0021-9258(18)47838-6
|View full text |Cite
|
Sign up to set email alerts
|

Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
11
0

Year Published

1990
1990
2018
2018

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 104 publications
(11 citation statements)
references
References 23 publications
0
11
0
Order By: Relevance
“…To confirm this hypothesis, we synthesized another glycoprotein, interferon (IFN)-β (Figure B, M9-IFN-β), having the same helical bundle structure as EPO, and used it for confirming substrate specificity of UGGT. IFN-β has the same number of amino acid residues, 166, and forms five helices structure . We synthesized IFN-β bearing an M9-glycan at the native glycosylation position, Asn80, using a three segment coupling strategy (synthesis is shown in SI, Figures S63–S70).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…To confirm this hypothesis, we synthesized another glycoprotein, interferon (IFN)-β (Figure B, M9-IFN-β), having the same helical bundle structure as EPO, and used it for confirming substrate specificity of UGGT. IFN-β has the same number of amino acid residues, 166, and forms five helices structure . We synthesized IFN-β bearing an M9-glycan at the native glycosylation position, Asn80, using a three segment coupling strategy (synthesis is shown in SI, Figures S63–S70).…”
Section: Resultsmentioning
confidence: 99%
“…IFN-β has the same number of amino acid residues, 166, and forms five helices structure. 29 We synthesized IFN-β bearing an M9glycan at the native glycosylation position, Asn80, using a three segment coupling strategy (synthesis is shown in SI, Figures S63−S70). 30 However, UGGT did not transfer a glucose residue onto this homogeneous native folded IFN-β (Figure 3A, right lane).…”
Section: Journal Of the American Chemical Societymentioning
confidence: 94%
“…Recombinant human interferon beta (IFNβ), a cytokine with anti-inflammatory and tumor-suppressor functions, is considered as the first choice treatment of multiple sclerosis, a severe neurodegenerative autoimmune disease . Interferon beta-1a (IFNβ1a), in contrast to interferon beta-1b (IFNβ1b), is glycosylated at asparagine 80 carrying mainly biantennary and triantennary glycan structures. , IFNβ1a has an average molecular weight of about 22.5 kDa, contains 166 amino acid residues, and is produced in Chinese hamster ovarian (CHO) cells . As described by Karpusas et al, the protein contains five alpha helices, an intramolecular disulfide bridge between cysteines in positions 31 and 141, and a free cysteine (Cys) in position 17.…”
Section: Introductionmentioning
confidence: 99%
“…Among other things, the application of mammalian cell culture has made it feasible to produce recombinant glycoproteins in quantities sufficient for pharmaceutical use. Mammalian-cell-expressed recombinant glycoproteins that are approved or under development as pharmaceutical agents include tissue plasminogen activator (2, 3), erythropoietin (4,5), soluble CD4 (6), factor VIII (7), and /3-interferon 0003-2700/90/0362-1714$02.50/0 (8,9). Of these, recombinant tissue plasminogen activator (rt-PA) and recombinant erythropoietin have been approved by the U.S. Food and Drug Administration for therapeutic use in humans, while most of the others are in clinical trials.…”
Section: Introductionmentioning
confidence: 99%